Dyne Therapeutics, Inc. (DYN) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Dyne Therapeutics, Inc. (DYN) posted $0 in revenue for fiscal 2025, with a net loss of $446.21M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. has grown revenue from $0 to $0 over the last 7 fiscal years.
It carries about $148.92M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Dyne Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Dyne Therapeutics, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-14.86M | $-59.44M | $-149.29M | $-168.10M | $-235.94M | $-317.42M | $-446.21M |
| Net margin | — | — | — | — | — | — | — |
Source: Dyne Therapeutics, Inc. SEC filings (10-K).
Dyne Therapeutics, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 219.9% over 4 years (51.6M → 165M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $148.9M of debt while last year's operating cash flow was negative ($-403.2M).
Explore 7 years of Dyne Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DYN in your portfolio →
Dyne Therapeutics, Inc. financial history by metric
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc. — frequently asked questions
What is Dyne Therapeutics, Inc.'s revenue?
Dyne Therapeutics, Inc. (DYN) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Dyne Therapeutics, Inc. profitable?
No — DYN reported a net loss of $-446.21M in fiscal 2025.
What is DYN's P/E ratio?
Dyne Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Dyne Therapeutics, Inc. have?
As of fiscal year 2025, DYN carried roughly $148.92M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Dyne Therapeutics, Inc.'s market cap?
Dyne Therapeutics, Inc. (DYN) has a market capitalization of about $2.97B, based on the latest data in our nightly-refreshed cache.
When does Dyne Therapeutics, Inc.'s fiscal year end?
DYN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Dyne Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.